Sodium 5- (2-Aminoethylamino) -1-naphthalenesulfonate

<strong>Sodium 5-(2-Aminoethylamino)-1-naphthalenesulfonate</strong>_x000D_ <strong>Catalog number:</strong> B2011012_x000D_ <strong>Lot number:</strong> Batch Dependent_x000D_ <strong>Expiration Date:</strong> Batch dependent_x000D_ <strong>Amount:</strong> 50 mg_x000D_ <strong>Molecular Weight or Concentration:</strong> 288.30 g/mol_x000D_ <strong>Supplied as:</strong> Powder_x000D_ <strong>Applications:</strong> molecular tool for various biochemical studies_x000D_ <strong>Storage:</strong> -20C_x000D_ <strong>Keywords:</strong>_x000D_ <strong>Grade:</strong> Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity &gt;18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ <strong>References:</strong>_x000D_ 1: Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance Oncogene. 2003 Oct 20;22(47):7359-68._x000D_ 2: Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, Tran T, Lynn J, Chen JY, Volkmer JP, Agoram B, Huang J, Majeti R, Weissman IL, Takimoto CH, Chao MP, Smith SM. CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma N Engl J Med. 2018 Nov 1;379(18):1711-1721._x000D_ 3: Jain N, Smith SW, Ghone S, Tomczuk B. Current ADC Linker Chemistry Pharm Res. 2015 Nov;32(11):3526-40._x000D_ 4: Smith SN, Schubert R, Simic B, Brücher D, Schmid M, Kirk N, Freitag PC, Gradinaru V, Plückthun A. The SHREAD gene therapy platform for paracrine delivery improves tumor localization and intratumoral effects of a clinical antibody Proc Natl Acad Sci U S A. 2021 May 25;118(21):e2017925118._x000D_ 5: Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH; HERMES Trial Group. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis N Engl J Med. 2008 Feb 14;358(7):676-88._x000D_ 6: Smith SD, Lopedote P, Samara Y, Mei M, Herrera AF, Winter AM, Hill BT, Shadman M, Ujjani C, Lynch RC, Jacobson CA, Kim AI, Caimi P, Milano F, Gopal AK. Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis Clin Lymphoma Myeloma Leuk. 2021 Mar;21(3):170-175._x000D_ 7: Schoeder CT, Schmitz S, Adolf-Bryfogle J, Sevy AM, Finn JA, Sauer MF, Bozhanova NG, Mueller BK, Sangha AK, Bonet J, Sheehan JH, Kuenze G, Marlow B, Smith ST, Woods H, Bender BJ, Martina CE, Del Alamo D, Kodali P, Gulsevin A, Schief WR, Correia BE, Crowe JE Jr, Meiler J, Moretti R. Modeling Immunity with Rosetta: Methods for Antibody and Antigen Design Biochemistry. 2021 Mar 23;60(11):825-846._x000D_ 8: Smith GP, Hood L, Fitch WM. Antibody diversity Annu Rev Biochem. 1971;40:969-1012._x000D_ 9: Abramson JS, Ghosh N, Smith SM. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma Am Soc Clin Oncol Educ Book. 2020 May;40:302-313._x000D_ <a href="https://pubmed.ncbi.nlm.nih.gov/30813769">10: Garland SG, Smith SM, Gums JG. Erenumab: A First-in-Class Monoclonal Antibody for Migraine Prevention Ann Pharmacother. 2019 Sep;53(9):933-939. </a>_x000D_ _x000D_ <strong>Products Related to Sodium 5-(2-Aminoethylamino)-1-naphthalenesulfonate</strong><a href="https://moleculardepot.com/product-category/Chemicals/">: Chemicals</a>